Clinical trials: PDAC
Metastatic Pancreatic Ductal Adenocarcinoma
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT02583477
- Testing
- MEDI4736 in combination with nab-paclitaxel and gemcitabine, MEDI4736 in combination with AZD5069
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 23 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with…
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC)
- Trial name
- NCT07349537
- Testing
- RMC-5127, daraxonrasib, cetuximab
- Where
- 9 sites in United States
- Volunteers
- 574 people
- Sponsor
- Revolution Medicines, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC)
A Study on Multimodal Prognostic Scoring of Advanced PDAC.
The aim of this study is to construct unimodal and multimodal prediction models for overall survival (OS), progression free survival (PFS), and treatment response (complete response+partial response) of advanced first-line…
- Trial name
- NCT07373691
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
This study is designed to explore the efficacy and safety of surufatinib combined with camrelizumab and AS (nab-paclitaxel and S-1) as first-line treatment compared with AG (nab-paclitaxel and gemcitabine) in unresectable…
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreas Cancer, Pancreatic Neoplasms
- Trial name
- NCT05218889
- Testing
- surufatinib + camrelizumab + nab-paclitaxel + S-1, nab-paclitaxel + gemcitabine
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Chinese PLA General Hospital
Pancreatic Adenocarcinoma, Weight Loss
Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)
The purpose of this study is to prospectively analyze the prevalence of SIBO in patients with Pancreatic adenocarcinoma (PDAC) and understand its association with weight loss and pancreatic resection status.
- Trial name
- SIBO in PDAC (NCT06988150)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Pancreatic Neoplasm
DDP ip Combined With AG in PDAC With Peritoneal Metastasis
intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel in patients with pancreatic cancer with peritoneal metastasis
- Trial name
- NCT05222204
- Testing
- intraperitoneal (IP) Cisplatin combined with intravenous gemcitabine + nab-paclitaxel
- Where
- 2 sites in China
- Volunteers
- 91 people
- Sponsor
- Fudan University
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
This is a prospective, single-center, randomized, open-label, two-arm Phase II clinical trial design to evaluate the feasibility, safety and preliminary efficacy of combining fecal Fecal Microbiota Transplantation （FMT） Combined…
- Trial name
- NCT07845565
- Testing
- FMT+Chemotherapy+Immunotherapy, Chemotherapy+Immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Metastatic Pancreatic Ductal Adenocarcinoma
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
The purpose of this study is to determine the safety and efficacy of pan KRAS inhibitor JAB-23E73 in combination with nab-paclitaxel and gemcitabine in participants with metastatic PDAC harboring KRAS gene alterations.
- Trial name
- NCT07640295
- Testing
- JAB-23E73 tablet，nab-paclitaxel，gemcitabine
- Where
- 13 sites in China
- Volunteers
- 80 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Solid Tumors
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
- Trial name
- DAWN-303 (NCT07522073)
- Testing
- INCB161734, Investigator's choice of chemotherapy
- Where
- 228 sites in United States, Australia and 20 more
- Volunteers
- 588 people
- Sponsor
- Incyte Corporation
Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC)
EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer
The EUS-AI-R study is an observational, single-center, two-phase (retrospective-prospective) study designed to develop and validate artificial intelligence (AI) models for predicting chemotherapy response and oncological outcomes…
- Conditions
- Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Artificial Intelligence (AI), Endoscopic Ultrasound (EUS)
- Trial name
- EUS-AI-R (NCT07803770)
- Testing
- Endoscopic ultrasound (EUS), with or without tissue acquisition (EUS-FNA/FNB), performed according to standard clinical practice. No study-specific intervention is introduced.
- Where
- Italy
- Volunteers
- 700 people
- Sponsor
- IRCCS San Raffaele
Pancreatic Adenocarcinoma
QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
This is a single-center, open-label, exploratory study to evaluate the efficacy and safety of QL1706 plus nab-paclitaxel and gemcitabine as first-line treatment in patients with unresectable locally advanced or metastatic…
- Trial name
- NCT06750861
- Testing
- QL1706
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
The investigators are developing a non-invasive breath test to help us detect pancreatic cancer earlier. The test detects small molecules called volatile organic compounds that are made by pancreatic cancers.
- Trial name
- NCT07243262
- Testing
- Breath test
- Where
- United Kingdom
- Volunteers
- 6,079 people
- Sponsor
- Imperial College London
Colorectal Cancer, Pancreatic Cancer
KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
Phase 1b study evaluating the efficacy and immune response to a synthetic long peptide mutant KRAS vaccine (SPL mKRASvax) combined with Balstilimab and Botensilimab for unresectable or metastatic mismatch repair-proficient…
- Trial name
- NCT06411691
- Testing
- KRAS Vaccine with Poly-ICLC adjuvant, Balstilimab, Botensilimab
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Adenocarcinoma, Pancreatic Intraepithelial Neoplasia
The LINFU® U.S. Registry for the Detection of Asymptomatic Pancreatic Ductal Adenocarcinoma
Adenocyte has developed LINFU®, (Low Intensity Non-Focused Ultrasound excitation of the pancreas) as a method of identifying early, asymptomatic pancreatic cancer and its noninvasive precancerous lesions.
- Trial name
- NCT06157671
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Adenocyte, LLC
Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma
Monitoring and Managing Glucose Levels in People With Pancreatic Cancer
This study will investigate the prevalence of hyperglycemia (high blood sugar) in approximately 50 participants with pancreatic cancer.
- Conditions
- Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Hyperglycemia
- Trial name
- PEGASUS (NCT05132244)
- Testing
- Glucose Measurements via Blood Draw
- Where
- 2 sites in Canada
- Volunteers
- 50 people
- Sponsor
- British Columbia Cancer Agency
Pancreatic Adenocarcinoma
Gemcitabine, Nab-Paclitaxel, Cisplatin and Anakinra Treatment on Patients With Pancreatic Cancer
The objective of this study is to improve survival by the addition of anakinra to the chemotherapy combination of nab-paclitaxel, gemcitabine, and cisplatin in patients with resectable or potentially resectable pancreatic…
- Trial name
- NCT02550327
- Testing
- Nab-paclitaxel, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Pancreatic Ductal Adenocarcinoma
Novel MRI Techniques for Pancreatic Cancer
The purpose of this study is to optimize magnetic resonance imaging (MRI) sequences for imaging pancreatic ductal adenocarcinoma and correlate MRI biomarkers with the expression of the tumor suppressor gene SMAD4 and clinical…
- Trial name
- NCT04306861
- Testing
- MRI
- Sponsor
- Beth Israel Deaconess Medical Center
Pancreatic Ductal Adenocarcinoma (PDAC)
OSCAR I STUDY - The ONCObind CTC Removal Study
This study is a Prospective Single Arm Open Label Feasibility trial to evaluate the initial safety and signal of efficacy of a novel extracorporeal blood purification (EBP) procedure in metastatic PDAC refractory to systemic…
- Trial name
- NCT06481397
- Testing
- ONCObind (Onco-Seraph) 100 Filter
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- ExThera Medical Corporation
Pancreatic Ductal Adenocarcinoma (PDAC)
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Pancreatic Cancer
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Pancreatic ductal adenocarcinoma (PDAC)
- Trial name
- NCT07301229
- Testing
- HLX43 DOSE 1 (2.5 mg/kg), HLX43 DOSE 2 (3.0 mg/kg)
- Volunteers
- 100 people
- Sponsor
- Shanghai Henlius Biotech
Metastatic Pancreatic Adenocarcinoma
Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.
MAZEPPA is open-label, phase II study to assess the efficacy of a genomic-driven maintenance therapy in terms of PFS in Pancreatic ductal adenocarcinoma (PDAC) patients with disease controlled after 4 months of mFOLFIRINOX…
- Trial name
- MAZEPPA (NCT04348045)
- Testing
- Arm A - Olaparib, ARM B - durvalumab plus selumetinib, ARM C FOLFIRI
- Where
- 29 sites in France
- Volunteers
- 307 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group